Uncategorized Archives - Page 3 of 137

MondayMay 19, 2025 2:30 pm

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell…

MondayMay 19, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Q1 milestones are representative of Soligenix’s commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. The company noted positive interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment. Soligenix announced the release of a publication describing the preclinical efficacy of CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments (https://ibn.fm/OMQmM). These milestones are representative of Soligenix’s continued…

MondayMay 19, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Experienced leadership contributes to key performance indicators. Dr. Eric Poma brings more than 30 years of experience to his new role as CLDI CEO. His expertise will help the company develop and advance proprietary groundbreaking therapies. Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi’s commitment to advancing its innovative cancer therapies under experienced guidance. Dr.…

TuesdayMay 13, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://ibn.fm/jhHMY). The…

FridayMay 09, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid…

WednesdayMay 07, 2025 10:30 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030. The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts. Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods. The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway. INBS is led by a seasoned executive team with global healthcare…

ThursdayMay 01, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer

The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030. SNGX’s HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL. HyBryte(TM) is a novel therapy based on photodynamic therapy, which combines light and a photosensitizer to target and destroy cancer cells. The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The…

WednesdayApr 30, 2025 10:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments. Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors. Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by…

WednesdayApr 30, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare

Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being…

TuesdayApr 29, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search